1
|
Abstract
Notwithstanding tremendous research efforts, the cause of Alzheimer's disease (AD) remains elusive and there is no curative treatment. The cholinergic hypothesis presented 35 years ago was the first major evidence-based hypothesis on the etiology of AD. It proposed that the depletion of brain acetylcholine was a primary cause of cognitive decline in advanced age and AD. It relied on a series of observations obtained in aged animals, elderly, and AD patients that pointed to dysfunctions of cholinergic basal forebrain, similarities between cognitive impairments induced by anticholinergic drugs and those found in advanced age and AD, and beneficial effects of drugs stimulating cholinergic activity. This review revisits these major results to show how this hypothesis provided the drive for the development of anticholinesterase inhibitor-based therapies of AD, the almost exclusively approved treatment in use despite transient and modest efficacy. New ideas for improving cholinergic therapies are also compared and discussed in light of the current revival of the cholinergic hypothesis on the basis of two sets of evidence from new animal models and refined imagery techniques in humans. First, human and animal studies agree in detecting signs of cholinergic dysfunctions much earlier than initially believed. Second, alterations of the cholinergic system are deeply intertwined with its reactive responses, providing the brain with efficient compensatory mechanisms to delay the conversion into AD. Active research in this field should provide new insight into development of multitherapies incorporating cholinergic manipulation, as well as early biomarkers of AD enabling earlier diagnostics. This is of prime importance to counteract a disease that is now recognized to start early in adult life.
Collapse
|
2
|
Bacopa monniera selectively attenuates suppressed Superoxide dismutase activity in Diazepam induced amnesic mice. Ann Neurosci 2014; 18:8-13. [PMID: 25205911 PMCID: PMC4117027 DOI: 10.5214/ans.0972.7531.1118104] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2010] [Revised: 12/10/2010] [Accepted: 01/04/2011] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND Amnesia is characterized by loss of memory that could result from abnormal neuro-chemical homeostasis, genetic predisposition or drug abuse. We earlier reported that B. monniera attenuates diazepam, scopolamine and L-NNA induced amnesia and wanted to test if SOD levels were affected by its administration. PURPOSE B. monniera is earlier reported to augment the defense system for oxidative stress by increasing the activities of superoxide dismutase, therefore, we investigated its levels after B. monniera administration in combination with different amnesic agents. METHODS We treated mice with amnesic agents such as scopolamine, diazepam, L-NNA and MK 801 either with or without B. monniera. RESULTS Diazepam (1.75 mg/kg ip) significantly reduced SOD activity while it was unaltered when Scopolamine (0.1 mg/kg ip), MK 801 (0.17 mg/kg ip) and L-NNA (30 mg/kg ip) were administered. B. monniera significantly attenuated diazepam induced suppression of SOD activity. CONCLUSION It is suggested that the mechanism of B. monniera's antiamnesic effect may vary depending on the type of amnesic agent used. However, antioxidant mechanism may be central to evoking the memory enhancing effects of B. monniera against diazepam induced amnesia.
Collapse
|
3
|
Talboom JS, West SG, Engler-Chiurazzi EB, Enders CK, Crain I, Bimonte-Nelson HA. Learning to remember: cognitive training-induced attenuation of age-related memory decline depends on sex and cognitive demand, and can transfer to untrained cognitive domains. Neurobiol Aging 2014; 35:2791-2802. [PMID: 25104561 DOI: 10.1016/j.neurobiolaging.2014.06.008] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2013] [Revised: 05/27/2014] [Accepted: 06/10/2014] [Indexed: 01/09/2023]
Abstract
Aging is associated with progressive changes in learning and memory. A potential approach to attenuate age-related cognitive decline is cognitive training. In this study, adult male and female rats were given either repeated exposure to a T-maze, or no exposure to any maze, and then tested on a final battery of cognitive tasks. Two groups of each sex were tested from 6 to 18 months old on the same T-maze; Group one received a version testing spatial reference memory, and Group two received only the procedural testing components with minimal cognitive demand. Groups three and four of each sex had no maze exposure until the final battery, and were comprised of aged or young rats, respectively. The final maze battery included the practiced T-maze plus two novel tasks, one with a similar, and one with a different, memory type to the practice task. Group five of each sex was not maze tested, serving as an aged control for the effects of maze testing on neurotrophin protein levels in cognitive brain regions. Results showed that adult intermittent cognitive training enhanced performance on the practice task when aged in both sexes, that cognitive training benefits transferred to novel tasks only in females, and that cognitive demand was necessary for these effects, since rats receiving only the procedural testing components showed no improvement on the final maze battery. Further, for both sexes, rats that showed faster learning when young demonstrated better memory when aged. Age-related increases in neurotrophin concentrations in several brain regions were revealed, which were related to performance on the training task only in females. This longitudinal study supports the tenet that cognitive training can help one remember later in life, with broader enhancements and associations with neurotrophins in females.
Collapse
Affiliation(s)
- Joshua S Talboom
- Department of Psychology, Arizona State University, Tempe, AZ, USA; Arizona Alzheimer's Consortium, Phoenix, AZ, USA
| | - Stephen G West
- Department of Psychology, Arizona State University, Tempe, AZ, USA; Arizona Alzheimer's Consortium, Phoenix, AZ, USA
| | - Elizabeth B Engler-Chiurazzi
- Department of Psychology, Arizona State University, Tempe, AZ, USA; Arizona Alzheimer's Consortium, Phoenix, AZ, USA
| | - Craig K Enders
- Department of Psychology, Arizona State University, Tempe, AZ, USA
| | - Ian Crain
- Department of Psychology, Arizona State University, Tempe, AZ, USA
| | - Heather A Bimonte-Nelson
- Department of Psychology, Arizona State University, Tempe, AZ, USA; Arizona Alzheimer's Consortium, Phoenix, AZ, USA.
| |
Collapse
|
4
|
Robinson L, Platt B, Riedel G. Involvement of the cholinergic system in conditioning and perceptual memory. Behav Brain Res 2011; 221:443-65. [PMID: 21315109 DOI: 10.1016/j.bbr.2011.01.055] [Citation(s) in RCA: 82] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2011] [Accepted: 01/29/2011] [Indexed: 01/07/2023]
Abstract
The cholinergic systems play a pivotal role in learning and memory, and have been the centre of attention when it comes to diseases containing cognitive deficits. It is therefore not surprising, that the cholinergic transmitter system has experienced detailed examination of its role in numerous behavioural situations not least with the perspective that cognition may be rescued with appropriate cholinergic 'boosters'. Here we reviewed the literature on (i) cholinergic lesions, (ii) pharmacological intervention of muscarinic or nicotinic system, or (iii) genetic deletion of selective receptor subtypes with respect to sensory discrimination and conditioning procedures. We consider visual, auditory, olfactory and somatosensory processing first before discussing more complex tasks such as startle responses, latent inhibition, negative patterning, eye blink and fear conditioning, and passive avoidance paradigms. An overarching reoccurring theme is that lesions of the cholinergic projection neurones of the basal forebrain impact negatively on acquisition learning in these paradigms and blockade of muscarinic (and to a lesser extent nicotinic) receptors in the target structures produce similar behavioural deficits. While these pertain mainly to impairments in acquisition learning, some rare cases extend to memory consolidation. Such single case observations warranted replication and more in-depth studies. Intriguingly, receptor blockade or receptor gene knockout repeatedly produced contradictory results (for example in fear conditioning) and combined studies, in which genetically altered mice are pharmacological manipulated, are so far missing. However, they are desperately needed to clarify underlying reasons for these contradictions. Consistently, stimulation of either muscarinic (mainly M(1)) or nicotinic (predominantly α7) receptors was beneficial for learning and memory formation across all paradigms supporting the notion that research into the development and mechanisms of novel and better cholinomimetics may prove useful in the treatment of neurodegenerative or psychiatric disorders with cognitive endophenotypes.
Collapse
Affiliation(s)
- Lianne Robinson
- School of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
| | | | | |
Collapse
|
5
|
Saraf MK, Prabhakar S, Khanduja KL, Anand A. Bacopa monniera Attenuates Scopolamine-Induced Impairment of Spatial Memory in Mice. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2011; 2011:236186. [PMID: 21607013 PMCID: PMC3095476 DOI: 10.1093/ecam/neq038] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/31/2009] [Accepted: 03/31/2010] [Indexed: 11/13/2022]
Abstract
Scopolamine, an anticholinergic, is an attractive amnesic agent for discerning the action of candidate antiamnesic drugs. Bacopa monniera Linn (Syn. Brahmi) is one such antiamnesic agent that is frequently used in the ancient Indian medical system. We have earlier reported the reversal of diazepam-induced amnesia with B. monniera. In this study we wanted to test if scopolamine-induced impairment of spatial memory can also be ameliorated by B. monniera using water maze mouse model. The objective of study was to study the effect of B. monniera on scopolamine-induced amnesia. We employed Morris water maze scale to test the amnesic effect of scopolamine and its reversal by B. monniera. Rotarod test was conducted to screen muscle coordination activity of mice. Scopolamine significantly impaired the acquisition and retrieval of memory producing both anterograde and retrograde amnesia. Bacopa monniera extract was able to reverse both anterograde and retrograde amnesia. We propose that B. monniera's effects on cholinergic system may be helpful for developing alternative therapeutic approaches for the treatment of Alzheimer's disease.
Collapse
Affiliation(s)
- Manish Kumar Saraf
- Department of Neurology, Post Graduate Institute of Medical Education and Research, Sector-12, Chandigarh 160012, India
| | | | | | | |
Collapse
|
6
|
Bimonte-Nelson HA, Acosta JI, Talboom JS. Neuroscientists as cartographers: mapping the crossroads of gonadal hormones, memory and age using animal models. Molecules 2010; 15:6050-105. [PMID: 20877209 PMCID: PMC3126862 DOI: 10.3390/molecules15096050] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2010] [Revised: 08/24/2010] [Accepted: 08/30/2010] [Indexed: 11/17/2022] Open
Abstract
Cognitive function is multidimensional and complex, and research in multiple species indicates it is considerably impacted by age and gonadal hormone milieu. One domain of cognitive function particularly susceptible to age-related decrements is spatial memory. Gonadal hormones can alter spatial memory, and they are potent modulators of brain microstructure and function in many of the same brain areas affected by aging. In this paper, we review decades of animal and human literature to support a tertiary model representing interactions between gonadal hormones, spatial cognition and age given that: 1) gonadal hormones change with age, 2) age impacts spatial learning and memory, and 3) gonadal hormones impact spatial learning and memory. While much has been discovered regarding these individual tenets, the compass for future aging research points toward clarifying the interactions that exist between these three points, and understanding mediating variables. Indeed, identifying and aligning the various components of the complex interactions between these tenets, including evaluations using basic science, systems, and clinical perspectives, is the optimal approach to attempt to converge the many findings that may currently appear contradictory. In fact, as discoveries are being made it is becoming clear that the findings across studies that appear contradictory are not contradictory at all. Rather, there are mediating variables that are influencing outcome and affecting the extent, and even the direction, of the effects that gonadal hormones have on cognition during aging. These mediating variables are just starting to be understood. By aligning basic scientific discoveries with clinical interpretations, we can maximize the opportunities for discoveries and subsequent interventions to allow individuals to "optimize their aging" and find their own map to cognitive health as aging ensues.
Collapse
Affiliation(s)
- Heather A. Bimonte-Nelson
- Department of Psychology, Arizona State University, Tempe, AZ 85287, USA
- Arizona Alzheimer’s Consortium, Phoenix, AZ 85006, USA; E-Mails: (J.I.A.); (J.S.T.)
| | - Jazmin I. Acosta
- Department of Psychology, Arizona State University, Tempe, AZ 85287, USA
- Arizona Alzheimer’s Consortium, Phoenix, AZ 85006, USA; E-Mails: (J.I.A.); (J.S.T.)
| | - Joshua S. Talboom
- Department of Psychology, Arizona State University, Tempe, AZ 85287, USA
- Arizona Alzheimer’s Consortium, Phoenix, AZ 85006, USA; E-Mails: (J.I.A.); (J.S.T.)
| |
Collapse
|
7
|
|
8
|
Carey GJ, Billard W, Binch H, Cohen-Williams M, Crosby G, Grzelak M, Guzik H, Kozlowski JA, Lowe DB, Pond AJ, Tedesco RP, Watkins RW, Coffin VL. SCH 57790, a selective muscarinic M(2) receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals. Eur J Pharmacol 2001; 431:189-200. [PMID: 11728425 DOI: 10.1016/s0014-2999(01)01440-6] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
The present studies were designed to assess whether the novel muscarinic M(2) receptor antagonist 4-cyclohexyl-alpha-[4[[4-methoxyphenyl]sulphinyl]-phenyl]-1-piperazineacetonitrile (SCH 57790) could increase acetylcholine release in the central nervous system (CNS) and enhance cognitive performance in rodents and nonhuman primates. In vivo microdialysis studies show that SCH 57790 (0.1-10 mg/kg, p.o.) produced dose-related increases in acetylcholine release from rat hippocampus, cortex, and striatum. SCH 57790 (0.003-1.0 mg/kg) increased retention times in young rat passive avoidance responding when given either before or after training. Also, SCH 57790 reversed scopolamine-induced deficits in mice in a passive avoidance task. In a working memory operant task in squirrel monkeys, administration of SCH 57790 (0.01-0.03 mg/kg) improved performance under a schedule of fixed-ratio discrimination with titrating delay. The effects observed with SCH 57790 in behavioral studies were qualitatively similar to the effects produced by the clinically used cholinesterase inhibitor donepezil, suggesting that blockade of muscarinic M(2) receptors is a viable approach to enhancing cognitive performance.
Collapse
Affiliation(s)
- G J Carey
- Pharmacia Corp., 301 Henrietta St., Kalamazoo, MI 49007, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Zhao Y, Ku YL, Hao XJ, Lee SS. Preparation of Analogues of Territrem B, a Potent AChE Inhibitor. Tetrahedron 2000. [DOI: 10.1016/s0040-4020(00)00817-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Rosier A, Cornette L, Orban GA. Scopolamine-induced impairment of delayed recognition of abstract visual shapes. Neuropsychobiology 2000; 37:98-103. [PMID: 9566275 DOI: 10.1159/000026486] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Since the limbic system, whose involvement in cognitive processes is well documented, constitutes a major central cholinergic area, the effect of cholinergic drugs on cognitive tasks has been studied extensively. In the present study, we used a long-term visual recognition task to evaluate the persistence of the scopolamine-induced anterograde amnesia beyond drug clearance intervals. Following memorization of a list of abstract shapes, subjects were evaluated on recognition performance immediately after encoding, and after a 3-day interval. Administration of scopolamine (0.4-0.8 mg) 70 min prior to encoding induced a significant (8-16%) deficit in delayed recognition performance. In contrast, a scopolamine challenge on delayed recognition following a drug-free encoding did not influence memory performance. In contrast, even at peak levels, scopolamine did not alter immediate recognition, detection or visual discriminative performances. Hence, the presence of scopolamine during the encoding of the shapes induced a significant long-term memory deficit that persisted after scopolamine clearance. Therefore, this paradigm is useful for imaging regional brain activation during impaired recognition without the confounding direct effects of scopolamine on cerebral blood flow or metabolism, two physiological variables underlying the indirect measurement of brain activation.
Collapse
Affiliation(s)
- A Rosier
- Laboratorium voor Neurofysiologie, KU Leuven Medical School, Belgium.
| | | | | |
Collapse
|
11
|
Abstract
The phenomenon of dissociated memory retrieval is observed when some influences (for example, pharmacological) on the brain result in specific changes of long-term memory. The purpose of present paper is to reveal possibilities of the phenomenon for study of long-term memory retrieval. Pharmacologically-induced dissociated states could be identified when the retrieval of responses learned before treatment is temporarily blocked by the drug influence, but the ability of the animals to learn new tasks is intact. Furthermore, memory traces that were formed in drugged state are not accessible for the retrieval in normal state and only the same drug treatment allows retrieving them. In the present work, dissociated learning of food-motivated tasks was carried out in Wistar rats with cholinesterase inhibitor physostigmine (0.5 mg/kg, intraperitonealy) or general anaesthetic sodium pentobarbital (15 mg/kg, intraperitonealy.). The retrieval of dissociated responses was studied under the influence of various doses of the same drugs. The results revealed the asymmetry of memory dissociation with physostigmine in contrast to pentobarbital-induced memory dissociation. Gradual access for the retrieval of dissociated memory traces after pharmacological modulation of cholinergic and GABA-ergic brain systems was shown. It was suggested an important role of hippocampus in memory dissociation, as a structure-performing match-mismatch operations between different retrieved memory traces.
Collapse
Affiliation(s)
- V I Arkhipov
- Institute of Theoretical and Experimental Biophysics, Pushchino, Moscow Region, Russia.
| |
Collapse
|
12
|
Capone F, Oliverio A, Pomponi M, Marta M, Gatta F, Pavone F. Effects of the novel acetylcholinesterase inhibitor N-octyl-1,2,3, 4-tetrahydro-9-aminoacridine on locomotor activity and avoidance learning in mice. Neurobiol Learn Mem 1999; 71:301-7. [PMID: 10196108 DOI: 10.1006/nlme.1998.3883] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The acetylcholinesterase reversible inhibitor N-octyl-1,2,3, 4-tetrahydro-9-aminoacridine (THA-C8) is a new synthesized derivative of tacrine (THA) characterized by an alkyl chain in the molecular structure which ameliorates the penetrability of the compound into the central nervous system. THA-C8 (0.1-5 mg/kg) significantly reduced spontaneous locomotor activity in CD1 mice at a dose of 3 mg/kg. Moreover, THA-C8 (0.2-2 mg/kg) significantly improved shuttle-box avoidance acquisition at doses (0.25, 0.3, 1 mg/kg) not affecting locomotion and that are much lower than the doses reported to be effective for THA in animal models. From the data reported it seems that the new compound could be interesting for therapeutic purposes.
Collapse
Affiliation(s)
- F Capone
- Dipartimento di Genetica e Biologia Molecolare, Università "La Sapienza,", Rome, Italy
| | | | | | | | | | | |
Collapse
|
13
|
Abstract
Cholinesterase inhibitors (ChEI) represent the drug of choice for Alzheimer's disease (AD) treatment. They produce significant improvement on cognitive as well as non-cognitive function for a period up to 1 year during the first 3 years following clinical diagnosis. The magnitude of cognitive improvements is similar for different ChEI, however, differences are seen with regard to incidence and severity of side effects, optimal ChE inhibition, pharmacokinetic properties and mode of administration.
Collapse
Affiliation(s)
- E Giacobini
- Department of Geriatrics, University Hospitals of Geneva, Switzerland
| |
Collapse
|
14
|
O'Neill J, Fitten LJ, Siembieda D, Halgren E, Kim E, Fisher A, Perryman K. Effects of AF102B and tacrine on delayed match-to-sample in monkeys. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22:665-78. [PMID: 9682279 DOI: 10.1016/s0278-5846(98)00029-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
1. Object working memory, a function which declines in aging and dementia, was tested in young and aged pretrained monkeys using a delayed match-to-sample task. 2. During drug treatment, monkeys were given the m 1 muscarinic agonist AF102B (0.1-2.1 mg/kg i.m.), the cholinesterase inhibitor tacrine (0.5-2.0 mg/kg p.o.), or vehicle controls in a repeated measures design to assess putative cognitive enhancement. 3. Both agents improved task performance in both young and aged monkeys, AF102B yielding equivalent or greater, and less variable, improvement than tacrine. 4. AF102B may represent a low-toxicity alternative to tacrine for the treatment of age-related memory disorders.
Collapse
Affiliation(s)
- J O'Neill
- Department of Veterans Affairs Wadsworth Medical Center, Los Angeles, CA, USA
| | | | | | | | | | | | | |
Collapse
|
15
|
Giacobini E. Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochem Int 1998; 32:413-9. [PMID: 9676739 DOI: 10.1016/s0197-0186(97)00124-1] [Citation(s) in RCA: 144] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
This review starts with an historical background of the pharmacological development of tacrine almost fifty years ago (1949). Tacrine is the first drug to be tested, clinically, on a large scale and to be registered (1993) for treatment of Alzheimer's disease. For the first time, clinical results of four second generation cholinesterase inhibitors (ChEI) (donepezil, ENA 713, eptastigmine and metrifonate) are reviewed and compared with other ChEI such as tacrine, physostigmine and galanthamine. Data based on more than 6000 patients show that second generation drugs are well tolerated and show evidence of clinical efficacy. Differences are mainly due to frequency of side effects, number of drop outs and percentage of improved patients. These results also demonstrate the presence of clinical efficacy for all ChEI tested so far. Clinical mechanism of action, levels of efficacy and differences among various ChEI are discussed. Future potential indications are suggested. The present data indicate that optimization of effects prolongation and maintenance of clinical gains will depend on further knowledge of the compounds pharmacodynamic properties.
Collapse
Affiliation(s)
- E Giacobini
- HUG, Belle-Idée, Department of Geriatrics, University Hospitals of Geneva, Thonex, Switzerland
| |
Collapse
|
16
|
Harder JA, Baker HF, Ridley RM. The role of the central cholinergic projections in cognition: implications of the effects of scopolamine on discrimination learning by monkeys. Brain Res Bull 1998; 45:319-26. [PMID: 9510426 DOI: 10.1016/s0361-9230(97)00381-x] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
In humans, administration of the cholinergic antagonist scopolamine impairs the encoding of information into long-term memory and has effects on other cognitive processes. It has been supposed that it is inhibition of the rising cholinergic projections from the basal forebrain, specifically from the basal nucleus of Meynert (NBM) to the neocortex and from the medial septum/vertical limb of the diagonal band of Broca (MS/VDB) to the hippocampus, that results in these cognitive impairments. In this paper, we describe the effects of scopolamine treatment in monkeys on learning different sorts of visual discrimination and visuospatial conditional tasks and compare these results to the effects of lesions of the rising cholinergic projections. Experiments in rodents in which these projections have been selectively destroyed have failed to produce a consensus view of the functions of these two areas. In particular, highly specific immunotoxic lesions of the NBM have largely failed to produce changes in task performance that can be interpreted as resulting from a cognitive impairment. In monkeys, lesions of the NBM produce modest or short-lasting, impairments in visual discrimination learning, retention, and reversal, whereas lesions of the MS/VDB produce large and permanent impairments of certain types of conditional learning. Similar impairments produced by scopolamine in monkeys and additive effects of lesions of the NBM or MS/VDB with scopolamine suggest that scopolamine has these effects by acting on the rising cholinergic pathways rather than on other cholinergic systems in the brain. It is argued that the rising cholinergic projections sustain the functions of the target areas; in the case of the hippocampus in humans, the function is usually regarded as being the analysis of information in a way that is pertinent to the formation of episodic memories and in the case of the neocortex, is the analysis of information in a manner that is relevant to the cognitive processing of on-going events and the acquisition of semantic knowledge.
Collapse
Affiliation(s)
- J A Harder
- MRC Comparative Cognition Team, Department of Experimental Psychology, Cambridge, UK
| | | | | |
Collapse
|
17
|
Iversen SD. The pharmacology of memory. COMPTES RENDUS DE L'ACADEMIE DES SCIENCES. SERIE III, SCIENCES DE LA VIE 1998; 321:209-15. [PMID: 9759343 DOI: 10.1016/s0764-4469(97)89824-1] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Neurotransmitters play a critical role in the brain circuits involved in various aspects of memory. The importance of acetylcholine is illustrated by the psychopathology of Alzheimer's disease. Cholinergic replacement therapy is now available for treating the cognitive decline associated with this form of degenerative disease. Dopamine in the prefrontal cortex also contributes to information storage, particularly working memory. In both cases efforts have been made to identify the receptor subtype involved and such information is essential if pharmacologically specific drugs are to be developed for cognitive enhancement.
Collapse
Affiliation(s)
- S D Iversen
- Department of Experimental Psychology, South Parks Road, Oxford OX1 3UD, UK.
| |
Collapse
|
18
|
Abstract
Alzheimer's disease involves progressive degeneration of the cortex and the limbic system. Loss of afferent forebrain neurochemical modulatory systems is also seen, most significantly of the basal forebrain cholinergic system. Drug discovery programmes have pursued enhancement of forebrain muscarinic function as a therapeutic target. The most promising muscarinic agonists described achieve functional selectivity as agonists as the M1/M3 receptors in the CNS and M2 antagonists. These compounds have fewer cardiac and other cholinergic side effects. In rodent and monkey models of reference and working memory, these compounds reverse the cognitive impairment induced with plopolamine. Acetylcholinesterase inhibitors are even more efficacious in these models.
Collapse
Affiliation(s)
- S D Iversen
- Department of Experimental Psychology, Oxford
| |
Collapse
|
19
|
|
20
|
Vivas NM, Màrmol F, Sallés J, Badia A, Dierssen M. Action on noradrenergic transmission of an anticholinesterase: 9-amino-1,2,3,4-tetrahydroacridine. Neuropharmacology 1995; 34:367-75. [PMID: 7566467 DOI: 10.1016/0028-3908(95)00003-o] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The mechanism by which 9-amino-1,2,3,4-tetrahydroacridine (THA) inhibits beta-adrenoceptor linked cyclic AMP formation and its possible relationship with the cholinergic system were studied. In addition, the effect of THA on alpha 1-adrenoceptor coupled transduction systems was also investigated. THA was not able to influence the concentration-response curve for forskolin indicating that it is not acting on the catalytic subunit of the adenylate cyclase complex. On the other hand a cholinergic component seems to participate in the action of THA on beta-adrenoceptor stimulated adenylate cyclase activity since the blockade of muscarinic receptors with atropine (10 microM) partially prevented the reduction in cyclic AMP formation attained by THA in the hippocampus, in isoprenaline-stimulated conditions. This effect is not reproducible by another potent anticholinesterase physostigmine. Moreover, THA at concentrations up to micromolar did not affect alpha 1-adrenoceptor stimulated cyclic AMP formation or phosphoinositide hydrolysis. In conclusion, the neuropharmacological profile of THA is not to be restricted to the cholinergic system and its effectiveness in improving age-associated cognitive deterioration may involve an action on the beta-adrenoceptor coupled signal transduction system. Moreover, the action of THA on the beta-adrenergic and cholinergic systems in the brain could be relevant to the amelioration of cognitive deterioration and could lead to the development of new therapeutic strategies.
Collapse
Affiliation(s)
- N M Vivas
- Departament de Farmacologia i Psiquiatria, Universitat Autònoma de Barcelona, Spain
| | | | | | | | | |
Collapse
|
21
|
Greig NH, Pei XF, Soncrant TT, Ingram DK, Brossi A. Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease. Med Res Rev 1995; 15:3-31. [PMID: 7898167 DOI: 10.1002/med.2610150103] [Citation(s) in RCA: 165] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- N H Greig
- Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892
| | | | | | | | | |
Collapse
|
22
|
Fitten LJ, Perryman KM, O'Neill J, Halgren E. Influence of cholinesterase inhibitors on cortical slow-wave activity in aging nonhuman primate. Pharmacol Biochem Behav 1994; 49:235-9. [PMID: 7816881 DOI: 10.1016/0091-3057(94)90483-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Substantial evidence has now accumulated suggesting that the cognitive decrements characteristic of Alzheimer's disease and, to a lesser degree, of normal aging, may result, at least in part, from degenerative changes in the cholinergic system innervating archi- and neocortices. This evidence for cholinergic degeneration in AD has provided the key rationale for many recent clinical trials utilizing cholinergic agents for the purpose of palliating cognitive loss. The basal forebrain cholinergic system plays an important function in electrocortical activation associated with behavioral arousal and cognitive functions. We recorded electrocortical changes from nonhuman primates following administration of potentially clinically useful cholinergic agonists as well as an antagonist. The cholinesterase inhibitors tacrine (THA) and, to a lesser extent, physostigmine (PHYSO) and amodiaquine (AMDQ), caused an upward shift in the frequency of the resting electrocortical activity, although scopolamine significantly slowed the activity below baseline levels. We believe these findings support the concept that the cholinergic system may play an important role in cognitive processes associated with cortical activation.
Collapse
Affiliation(s)
- L J Fitten
- Psychiatry Service, Department of Veterans Affairs Medical Center, Sepulveda, CA 91343
| | | | | | | |
Collapse
|
23
|
Wagstaff AJ, McTavish D. Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging 1994; 4:510-40. [PMID: 7521234 DOI: 10.2165/00002512-199404060-00006] [Citation(s) in RCA: 93] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Tacrine is a centrally acting cholinesterase inhibitor with additional pharmacological activity on monoamine levels and ion channels. It has been postulated that some or all of these additional properties may also be relevant to the mode of action of the drug. There are wide interindividual variations in pharmacological and clinical response to tacrine, possibly related to interindividual variation in bioavailability. Tacrine appears to improve cognitive function and behavioural deficits in a proportion of patients with Alzheimer's disease, at dosages of 80 to 160 mg/day. In the best designed trials, 30 to 51% of evaluable patients showed an improvement of at least 4 points on the cognitive subscale of the Alzheimer's Disease Assessment Scale, versus 16 to 25% of placebo recipients. A similar proportion of tacrine recipients were judged to have improved when global assessment scales were used. There was a significant dose-response relationship up to 160 mg/day. However, large numbers of patients were withdrawn during the trials, many because of tacrine-associated increases in transaminase levels. Elevated liver enzyme levels occurred in about 50% of tacrine recipients (reaching clinical significance in about 25%). Cholinergic symptoms also occurred more often in tacrine recipients than in those receiving placebo. A gradual increase in tacrine dosage, at 6-week intervals, is recommended when initiating therapy, and weekly serum transaminase monitoring is required for 6 weeks after each dosage increase. Despite the limitations implied by the low proportion of responders and high incidence of hepatic adverse effects associated with therapy, tacrine appears to make a measurable difference in both cognitive and behavioural function in a proportion of patients with Alzheimer's disease--a welcome advance in an area previously devoid of acceptable treatment options.
Collapse
Affiliation(s)
- A J Wagstaff
- Adis International Limited, Auckland, New Zealand
| | | |
Collapse
|
24
|
Keseberg U, Schmidt WJ. Tetrahydroaminoacridine attenuates dizocilpine-induced behavioural changes. Behav Brain Res 1993; 53:113-8. [PMID: 8466656 DOI: 10.1016/s0166-4328(05)80270-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The acetylcholinesterase inhibitor tetrahydroaminoacridine (THA) is known to interact with neurotransmitter systems other than the cholinergic, e.g. several studies have shown interaction of THA with the N-methyl-D-aspartate (NMDA) receptor subtype of the glutamatergic system. We therefore investigated whether behavioral changes in rats, caused by the non-competitive NMDA-antagonist dizocilpine, were altered by THA. Spontaneous locomotion was measured in an open field and learning behaviour was evaluated in a spatial learning task in the 8-arm radial maze. Hyperactivity in the open field caused by 0.08 mg/kg i.p. dizocilpine was reversed by 5 mg/kg i.p. THA. Hyperactivity caused by 0.16 mg/kg i.p. dizocilpine was reversed by two THA doses (2.5 mg/kg, 5 mg/kg i.p.). A dizocilpine-induced acquisition deficit in the 8-arm radial maze was attenuated by THA (2.5 mg/kg) on the 6th and 7th day of testing. The effects of THA are discussed with reference to a possible functional glutamate agonism.
Collapse
Affiliation(s)
- U Keseberg
- University of Tübingen, Zoological Institute, Neuropharmacology Division, FRG
| | | |
Collapse
|
25
|
Iijima S, Greig NH, Garofalo P, Spangler EL, Heller B, Brossi A, Ingram DK. Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze. Psychopharmacology (Berl) 1993; 112:415-20. [PMID: 7871051 DOI: 10.1007/bf02244888] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Phenserine ((-)-N-phenylcarbamoyl eseroline), a carbamate analog of physostigmine (Phy), is a long-acting inhibitor of cholinesterase. We have assessed the potential clinical value of phenserine for cholinomimetic therapy of cognitive impairments associated with aging and Alzheimer's disease by evaluating its duration of in vivo activity against rat plasma acetylcholinesterase (AChE) and its effect on attenuating a scopolamine-induced impairment in learning performance of young rats in a shock-motivated 14-unit T-maze. Phenserine achieved maximum AChE inhibition of 73.5% at 5 min and maintained a high and relatively constant inhibition for more than 8 h. For analysis of effects on learning performance, 69, 3-month-old male Fischer-344 rats were pretrained in a straight runway to avoid electric footshock. On the following day, each animal received 15 trials in the 14-unit T-maze. Sixty minutes prior to the maze training, each rat received the first IP injection of either vehicle (Tween 80, ethanol and 0.9% NaCl) or phenserine at 1.5, 3.0, 4.0, 5.0, 7.5, or 10.0 mg/kg. Then 30 min prior to the training, each animal received a second IP injection of either 0.9% NaCl or scopolamine hydrochloride (0.75 mg/kg; SCOP). Compared to the vehicle-SCOP group, all but the 7.5 mg/kg dose of phenserine significantly ameliorated error performance, runtime, shock frequency and shock duration in SCOP-treated rats at the final block of three trials. Appearing to have a long effect and a wide therapeutic window, phenserine deserves further study as a cognitive enhancer.
Collapse
Affiliation(s)
- S Iijima
- Molecular Physiology and Genetics Section, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224
| | | | | | | | | | | | | |
Collapse
|
26
|
Rupniak NM, Tye SJ, Brazell C, Heald A, Iversen SD, Pagella PG. Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates. J Neurol Sci 1992; 107:246-9. [PMID: 1564524 DOI: 10.1016/0022-510x(92)90296-w] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Cholinergic replacement therapy for Alzheimer's disease using existing cholinesterase inhibitors is compromised by short duration, meagre benefits restricted to subgroups of patients, and peripheral toxicity. Heptyl physostigmine is a lipophilic carbamate derivative of physostigmine. In rhesus monkeys, heptyl physostigmine (0.2-0.9 mg/kg i.m.) fully reversed a scopolamine-induced cognitive impairment. Following oral administration in squirrel monkeys, heptyl physostigmine (8 mg/kg) induced long-lasting hypothermia (greater than or equal to 4 h), a centrally-mediated cholinergic effect. Erythrocyte acetylcholinesterase activity was inhibited by 86% at the time of peak hypothermia (180 min). Clinical trials with heptyl physostigmine will enable a more rigorous evaluation of cholinomimetic therapy for dementia.
Collapse
Affiliation(s)
- N M Rupniak
- Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, U.K
| | | | | | | | | | | |
Collapse
|
27
|
Profile of cholinomimetic drugs in primates: Status of screens for potential Alzheimer therapies. Drug Dev Res 1992. [DOI: 10.1002/ddr.430270202] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
28
|
Ravel N, Vigouroux M, Elaagouby A, Gervais R. Scopolamine impairs delayed matching in an olfactory task in rats. Psychopharmacology (Berl) 1992; 109:439-43. [PMID: 1365859 DOI: 10.1007/bf02247720] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The action of the cerebral cholinergic system seems to be important for remembering events over short time intervals. We decided to test this hypothesis in the rat by developing an original model of short term memory based on the olfactory sensory modality which is a major determinant in the animal behaviour. The principle of the experiment was a "delayed match-to-sample" test performed in a classical T maze divided into two compartments. In the first compartment, rats received an odorant stimulation, then, in the second, they had to discriminate between the two arms odorized differently. To receive a food reinforcement, the animals had to enter the arm signaled by the odor presented in the first part of the maze. The test was performed with (Short-term memory condition) or without (Immediate memory condition) a variable delay between the first odor sampling and the discrimination task. Both tests were performed with control and scopolamine-treated animals (0.5, 0.125 and 0.0625 mg/kg IP). An injection of scopolamine (0.5 mg/kg) impaired performances, even when no retention of the odor was required. However, lower doses (0.125, 0.0625 mg/kg) selectively altered performances in the short term memory condition. These results suggest that intact muscarinic transmission is required for an olfactory cue to be used over a short time after its presentation.
Collapse
Affiliation(s)
- N Ravel
- Laboratoire de Physiologie Neurosensorielle, Université Lyon I-CNRS URA 180, Villeurbanne, France
| | | | | | | |
Collapse
|
29
|
Rupniak NM, Samson NA, Tye SJ, Field MJ, Iversen SD. Evidence against a specific effect of cholinergic drugs on spatial memory in primates. Behav Brain Res 1991; 43:1-6. [PMID: 1859616 DOI: 10.1016/s0166-4328(05)80047-6] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
A scopolamine-like delay-dependent impairment in spatial delayed response performance in rhesus monkeys was induced by irrelevant interpolated activity or by using extended retention intervals. Physostigmine readily reversed the effects of scopolamine but had no effect on performance in young monkeys performing an irrelevant distractor task or in monkeys tested using extended retention intervals. Reducing stimulus control did not impair performance and did not alter the dose-response curve for induction of a deficit by scopolamine. Reducing the stimulus presentation time impaired performance across all retention intervals in a way which did not resemble the effect of scopolamine and which disappeared with practice. Our findings do not support the proposal that physostigmine interacts specifically with short-term spatial memory in primates.
Collapse
Affiliation(s)
- N M Rupniak
- Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, U.K
| | | | | | | | | |
Collapse
|